Overview

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic condition characterised by gastrointestinal inflammation. Its prevalence has been rising globally, affecting millions of individuals, particularly in developed countries.¹ IBD significantly impacts patients' quality of life, causing debilitating symptoms such as abdominal pain, diarrhoea, and weight loss. The condition often necessitates long-term treatment strategies.² With this growing health challenge, there is an increasing need for innovative therapies that reflect the realities of patient experiences outside controlled clinical environments.

This article explores how real-world evidence (RWE) bridges the gap between clinical research and treating IBD. Unlike randomised clinical trials, which are conducted under strict protocols, RWE utilises data from everyday clinical practice, providing insights into how treatments perform in diverse, unselected populations. This article aims to illustrate how RWE is integral in guiding therapeutic decisions and improving patient outcomes by validating the effectiveness of new IBD therapies in real-world settings.

Various data sources contribute to RWE, such as electronic health records, registries, and observational studies, offering a broader understanding of treatment impacts. By capturing outcomes that may not be evident in clinical trials, RWE plays a crucial role in supporting decision-making for clinicians and researchers in the development and refinement of IBD therapies​.²

Enhancing IBD treatment with real-world evidence role of real-world evidence

RWE complements clinical trial data by offering a broader perspective on drug performance, particularly in real-world settings where patient populations are more diverse.

Data sources for RWE

RWE primarily derives from registries, observational studies, and patient-reported outcomes (PROs). Registries collect detailed, long-term data from IBD patients, offering valuable insights into disease progression, treatment patterns, and outcomes.^3,4 Observational studies capture the effects of treatments outside of controlled environments.^3,4 There are two types of observational studies, prospective studies gather current data, while retrospective studies look at past data. PROs, collected through questionnaires and surveys, provide direct feedback from patients on their quality of life, symptom severity, and overall treatment satisfaction.²

Advantages of clinical trials

While randomised controlled trials (RCTs) are the gold standard for assessing drug efficacy, they often involve highly selective patient populations and controlled conditions that may not fully reflect real-world scenarios. RWE captures data from more diverse populations, including those with diseases patients suffer along with the main illness or varying disease severities, offering a more comprehensive view of treatment effectiveness and safety in everyday clinical practice.^3,4 This allows researchers to assess how therapies perform under typical clinical conditions, providing insights into drug interactions, adherence, and long-term outcomes that RCTs may miss.²

Examples of RWE in IBD therapies

In real-world studies, biologics like infliximab and adalimumab have shown sustained effectiveness and safety across diverse patient populations, reinforcing their role as key treatments in IBD. These findings, derived from RWE, have been instrumental in validating the long-term benefits and safety profiles of both biologics and small molecules in everyday clinical practice.^3,4 Likewise, small molecules like tofacitinib have also been assessed for real-world effectiveness, leading to adjustments in dosing guidelines and improved safety monitoring practices.²

Therapeutic decision-making in IBD using RWE

Clinical application

Building on these insights, RWE further informs therapeutic decision-making by helping clinicians tailor treatments based on data from everyday clinical practice. RWE informs decisions on drug choice, dosage adjustments, and treatment sequencing, helping clinicians assess the effectiveness of therapies across broader populations. This approach provides a more accurate representation of patient responses to treatments such as biologics and small molecules.⁵ RWE also helps in identifying subgroups of patients who may benefit from specific therapies, optimising care and improving outcomes.⁶

Case studies

Several case studies highlight how RWE has influenced treatment strategies for IBD. For example, studies involving golimumab for ulcerative colitis revealed that the drug’s effectiveness in real-world settings differed from clinical trials, prompting adjustments in dosing strategies and monitoring techniques. Observational studies on biologics like infliximab and adalimumab also demonstrated varying patient responses depending on previous anti-TNF exposure.^7,8 These real-world observations have guided the sequencing of biologics, with physicians opting to switch therapies based on RWE-driven insights into treatment durability and patient outcomes​.^5,6

Challenges

Despite its value, the use of RWE in clinical practice faces challenges, including data variability due to differing collection methods and patient demographics. Variability in data quality, incomplete records, and inconsistencies across registries can lead to difficulties in drawing standardised conclusions. To overcome these challenges, efforts are underway to harmonise data collection protocols, standardise outcome measures, and enhance digital tools for capturing comprehensive patient data. By improving data quality and standardisation, RWE can be more effectively utilised in therapeutic decision-making for IBD​.⁶

Monitoring and optimising IBD therapies with RWE

Patient monitoring

RWE plays a critical role in the continuous monitoring of patients with IBD. Physicians can leverage data from registries, electronic health records, and patient-reported outcomes (PROs) to track the effectiveness of treatments in real-time. This continuous monitoring allows for timely adjustments to therapies, ensuring that patients receive optimal care based on how their disease responds to treatment. For instance, RWE provides insights into flare-ups, treatment adherence, and the long-term impact of therapies on patient health.⁹ This enables more responsive care, tailored to the individual patient’s evolving condition.

Optimising treatment strategies

RWE is instrumental in refining treatment strategies for IBD. By analysing data from diverse patient populations, RWE helps physicians identify the most effective treatments for specific subgroups of patients. It also aids in determining the best sequencing of therapies, such as biologics and small molecules, ensuring that patients receive the right treatment at the right time. For example, RWE has shown that early intervention with anti-TNF agents, which block tumour necrosis factor to reduce inflammation, can lead to better long-term outcomes in patients with Crohn’s disease, influencing treatment algorithms.⁹ RWE also informs decisions on whether to intensify or de-escalate treatment based on patient response.

Impact on patient outcomes

The integration of real-time data through RWE creates a feedback loop that improves patient care and reduces complications. By utilising RWE, healthcare providers can make informed, evidence-based decisions that lead to more effective management of IBD. Studies have shown that using RWE-driven insights to adjust treatments can reduce hospitalisation rates, minimise disease progression, and enhance overall quality of life.⁹ As a result, patients benefit from personalised care that is continuously optimised, leading to fewer complications and better long-term health outcomes.

Summary

In conclusion, RWE is crucial in bridging the gap between clinical research and practical treatment for IBD. By integrating diverse data sources such as patient registries, electronic health records, and observational studies, RWE offers critical insights into the real-world effectiveness and safety of therapies. This evidence complements clinical trials by providing a fuller understanding of treatment outcomes across broader patient populations, enabling clinicians to optimise therapeutic strategies for IBD.

Looking ahead, advancements in RWE will include integrating advanced analytics and artificial intelligence to better predict treatment responses and disease progression. Improved digital platforms for real-time data collection will also enhance personalised treatment plans. Efforts to standardise RWE methodologies are underway, aiming to improve data consistency and reliability for guiding clinical decisions.

In summary, RWE will continue to play a pivotal role in advancing personalised medicine for IBD. By embracing RWE, healthcare providers can deliver more tailored treatment plans, improve patient outcomes, and reduce complications, ensuring that therapies reflect real-world patient experiences.